Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Front Pharmacol. 2022 Mar 22:13:886343. doi: 10.3389/fphar.2022.886343. eCollection 2022.

Wen-Hsuan Tsai¹, Fung-Chang Sung^{2

3

4}, Lu-Ting Chiu², Ying-Hsiu Shih², Ming-Chieh Tsai¹, Shu-I Wu^{5

6}

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
² Management Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taipei, Taiwan.
³ Department of Health Services Administration, China Medical University, College of Public Health, Taichung, Taiwan.
⁴ Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan.
⁵ Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
⁶ Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.765446.].

Keywords: anxiety; depression; diabetes; glucagon-like peptide-1 receptor agonist; neuroendocrine.